Bayer soars 18%, the largest increase in 23 years! The U.S. Supreme Court rejects Roundup cancer lawsuit, bringing a turnaround for tens of billions in lawsuits over the past decade.

```

The U.S. Supreme Court, by a 7-2 vote, ruled that consumers cannot sue Bayer over its Roundup herbicide's lack of a cancer warning, providing a crucial legal shield for the German pharmaceutical and agrochemical giant. This decision is expected to end nearly a decade of lawsuits that have cost Bayer more than $10 billion.

The majority opinion of the Court held that federal regulators had determined that Roundup did not require a cancer warning, so consumers could not use state law's "failure to warn" provisions to sue Bayer. The case overturned was a $1.25 million jury verdict awarded to a Missouri man who developed non-Hodgkin's lymphoma.

After the news was announced, Bayer's stock price in Frankfurt surged more than 18% at one point, marking its biggest one-day gain since March 2003, before trading was halted due to excessive volatility.

In a statement, Bayer said the ruling was "a win for science, farmers, and industries that rely on regulatory certainty to drive innovation," and predicted that it would lead to the dismissal of existing related lawsuits and block future claims of this nature.

Federal Preemption Principle Central to Decision

Justice Brett Kavanaugh wrote in the majority opinion that federal law "requires" pesticide labeling to be uniform, and that state law's "failure to warn" claims would force the addition of a cancer warning to Roundup's label, a requirement that "conflicts with and exceeds" EPA-approved label regulations.

The core legal basis of the case is the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which requires compliant labeling for pesticides and explicitly prohibits states from imposing additional requirements.

Bayer argued that once the EPA approves a Roundup label without a cancer warning, the company no longer faces legal risk for failing to provide such a warning.

Justices Ketanji Brown Jackson and Neil Gorsuch dissented. John Durnell’s attorney argued that the EPA’s determination does not prevent a state court from independently judging the necessity of a warning.

A Turning Point for Decade-Long Litigation?

Bayer acquired Monsanto, the manufacturer of Roundup, for $63 billion in 2018, thus inheriting a massive legal liability. The ongoing litigation cloud has weighed on Bayer’s stock for years; according to Bloomberg, CEO Bill Anderson has even considered whether the company should continue producing glyphosate.

Bloomberg Industry Research analyst Holly Froum estimated before the ruling that roughly $787 million worth of Roundup verdicts might be affected by the decision. Meanwhile, Bayer is actively advancing a $7.25 billion class-action settlement proposal, hoping Roundup users will participate and aiming to completely end the related litigation by year’s end.

Politically, in February this year, Trump took measures to encourage domestic glyphosate production and provided administrative support to Bayer in this case. However, this position runs counter to the "Make America Healthy Again" campaign, which advocates for removing glyphosate from the food supply chain.

Consumer and food safety advocacy groups supporting the plaintiffs have criticized the EPA review process as having loopholes, data gaps, and corporate influence over regulators, arguing that federal oversight is not a substitute for independent judicial decisions by state courts.

Risk Notice and DisclaimerThe market involves risk, and investments need to be made with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinion, viewpoint, or conclusion in this article suits their particular circumstances. Any investment made accordingly is at one’s own risk. ```